Patents by Inventor Patrick C. Roche

Patrick C. Roche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200270348
    Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.
    Type: Application
    Filed: May 11, 2020
    Publication date: August 27, 2020
    Inventors: Marcin KOWANETZ, Hartmut KOEPPEN, Zachary BOYD, Zhiming LIAO, Yifei ZHU, Bharathi VENNAPUSA, Patrick C. ROCHE
  • Patent number: 10689445
    Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: June 23, 2020
    Assignees: Ventana Medical Systems, Inc., Spring BioScience Corporation
    Inventors: Marcin Kowanetz, Hartmut Koeppen, Zachary Boyd, Zhiming Liao, Yifei Zhu, Bharathi Vennapusa, Patrick C. Roche
  • Patent number: 10179815
    Abstract: The present invention relates to isolated antibodies, or an antigen portions thereof, which bind to human HER3. The novel antibodies are of great utility since they allow for the sensitive and specific detection of human HER3. Detection of human HER3 is, e.g., possible in a tissue sample, even when such tissue sample is a formalin-fixed paraffin embedded tissue (FFPET) sample.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: January 15, 2019
    Assignees: VENTANA MEDICAL SYSTEMS, INC., ROCHE MOLECULAR SYSTEMS, INC.
    Inventors: Monika Soukupova, Michael Schraeml, Birgit Bossenmaier, Patrick C. Roche, Michael Gerg, Sebastian Dziadek
  • Publication number: 20180340231
    Abstract: Described herein are innovations for classifying subtypes of DLBCL, as well as using the results of classification for diagnosis, prognosis, and therapy selection. In this way, the classifier can effectively classify subtypes of DLBCL and provide meaningful output for the benefit of medical practices and DLBCL patients. Also described are arrays and kits that can be used to measure expression of DLBCL signatures genes.
    Type: Application
    Filed: September 29, 2016
    Publication date: November 29, 2018
    Applicant: HTG Molecular Diagnostics, Inc.
    Inventors: Bonnie LaFleur, Qian Liu, John W. Luecke, Patrick C. Roche
  • Publication number: 20180022809
    Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.
    Type: Application
    Filed: October 6, 2017
    Publication date: January 25, 2018
    Inventors: Marcin KOWANETZ, Hartmut KOEPPEN, Zachary BOYD, Zhiming LIAO, Yifei ZHU, Bharathi VENNAPUSA, Patrick C. ROCHE
  • Patent number: 9869617
    Abstract: Methods, kits, and systems for clarifying obfuscating pigments in histology samples such as an automated method of treating a histology sample with a clarifying reagent so that the clarifying reagent, contacts the sample and the pigments within the sample are decolorized , thus alleviating staining obfuscations associated with pigments. Decolorizing the pigments within the sample enables the histology sample to be interpretable by a qualified reader. An antigen retrieval step is performed after the clarification step.
    Type: Grant
    Filed: October 7, 2013
    Date of Patent: January 16, 2018
    Assignee: VENTANA MEDICAL SYSTEMS, INC.
    Inventors: Patricia Carrigan, James Grille, Greg Martin, Mark Robida, Patrick C. Roche
  • Publication number: 20170096487
    Abstract: The present invention relates to isolated antibodies, or an antigen portions thereof, which bind to human HER3. The novel antibodies are of great utility since they allow for the sensitive and specific detection of human HER3. Detection of human HER3 is, e.g., possible in a tissue sample, even when such tissue sample is a formalin-fixed paraffin embedded tissue (FFPET) sample.
    Type: Application
    Filed: March 29, 2016
    Publication date: April 6, 2017
    Inventors: Monika Soukupova, Michael Schraeml, Birgit Bossenmaier, Patrick C. Roche, Michael Gerg, Sebastian Dziadek
  • Publication number: 20160009805
    Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.
    Type: Application
    Filed: May 29, 2015
    Publication date: January 14, 2016
    Inventors: Marcin KOWANETZ, Hartmut KOEPPEN, Zachary BOYD, Zhiming LIAO, Yifei ZHU, Bharathi VENNAPUSA, Patrick C. ROCHE
  • Publication number: 20150276563
    Abstract: Methods, kits, and systems for clarifying biological samples containing obfuscating pigment are disclosed. An automated method of treating a sample mounted on a substrate to alleviate staining obfuscations associated with pigments within the sample includes applying a clarifying reagent so that the clarifying reagent contacts the sample and the pigments within the sample are decolorized. The pigments within the sample being decolorized enable the specifically stained sample to be interpretable by a qualified reader.
    Type: Application
    Filed: October 7, 2013
    Publication date: October 1, 2015
    Inventors: Patricia Carrigan, James Grille, Greg Martin, Mark Robida, Patrick C. Roche
  • Patent number: 8329421
    Abstract: Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the disclosed antigen-binding molecules. Thus, such antigen-binding molecules are useful at least to interrogate the regulated state of EGFR, predict the response of a cancer patient to EGFR inhibitor therapies, and/or predict the aggressiveness of neoplasms.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: December 11, 2012
    Assignee: Ventana Medical Systems, Inc.
    Inventors: William C. Powell, Linda Willoughby Kivi, Patrick C. Roche, Gary Gooch, Fabien Gaire
  • Publication number: 20100285025
    Abstract: Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the disclosed antigen-binding molecules. Thus, such antigen-binding molecules are useful at least to interrogate the regulated state of EGFR, predict the response of a cancer patient to EGFR inhibitor therapies, and/or predict the aggressiveness of neoplasms.
    Type: Application
    Filed: July 11, 2008
    Publication date: November 11, 2010
    Inventors: William C. Powell, Linda Willoughby Kivi, Patrick C. Roche, Gary Gooch, Fabien Gaire
  • Publication number: 20090017050
    Abstract: Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the disclosed antigen-binding molecules. Thus, such antigen-binding molecules are useful at least to interrogate the regulated state of EGFR, predict the response of a cancer patient to EGFR inhibitor therapies, and/or predict the aggressiveness of neoplasms.
    Type: Application
    Filed: July 11, 2008
    Publication date: January 15, 2009
    Inventors: William C. Powell, Linda Willoughby Kivi, Patrick C. Roche, Gary Gooch, Fabien Gaire
  • Publication number: 20030198961
    Abstract: The invention provides materials and methods for determining the aggressiveness of a cancer in a mammal. Specifically, the invention provides methods and methods for measuring the level of a TIEG marker in a sample. Such levels can be correlated with the aggressiveness of a cancer to predict patient outcome and develop treatment regimens.
    Type: Application
    Filed: April 15, 2002
    Publication date: October 23, 2003
    Inventors: Thomas C. Spelsberg, Patrick C. Roche, Monica Reinholz, Steven A. Johnsen, Malayannan Subramaniam
  • Patent number: 6207375
    Abstract: Methods to determine TIEF-1 polypeptide, or genetic rearrangements in the TIEF-1 gene, in a sample are provided. Also provided are TIEF-1 specific antibodies and nucleic acid probes, and methods of employing those antibodies and probes to detect breast cancer in situ in a mammalian tissue sample.
    Type: Grant
    Filed: July 7, 1998
    Date of Patent: March 27, 2001
    Assignee: Mayo Foundation for Medical Educational & Research
    Inventors: Malayannan Subramaniam, Thomas C. Spelsberg, Patrick C. Roche
  • Patent number: 5891651
    Abstract: A method of recovering colorectal epithelial cells or fragments thereof from a stool sample is provided. The method involves contacting a stool sample with a specific binding reagent having specificity for colorectal epithelial cells or membrane fragments thereof to form a complex containing the specific binding reagent and the colorectal epithelial cells or fragments thereof, and separating the complex from the sample. A method of detecting dysplastic colorectal epithelial cells or fragments thereof, wherein a specific binding reagent employed in the method has specificity for dysplastic colorectal epithelial cells or membrane fragments thereof, is also provided. An article of manufacture containing reagents for performing the method is further provided.
    Type: Grant
    Filed: March 29, 1996
    Date of Patent: April 6, 1999
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Patrick C. Roche, George G. Klee, Paul J. Limburg, David A. Ahlquist